Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNB1 | Q14721 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22242020 | 0.87 | ACACB (0.40) | ACACBADRB1HCRTR1HCRTR2 | |
| SCHEMBL24347506 | 0.76 | HCRTR1 (0.34) | KCNB1SMN1; SMN2KCNA5HCRTR1HCRTR2 | |
| SCHEMBL24347354 | 0.76 | HCRTR1 (0.39) | SMN1; SMN2LMNAHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL14868372 | 0.76 | ADRB1 (0.41) | LMNAADRB1HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL29799828 | 0.74 | SYK (0.36) | ADRB1HCRTR1HCRTR2KMT2AMAPT | |
| SCHEMBL24347482 | 0.72 | ADORA2A (0.48) | SMN1; SMN2HCRTR1HCRTR2MAPT | |
| SCHEMBL29676316 | 0.72 | ACACB (0.53) | ACACBADRB1 | |
| SCHEMBL20889867 | 0.70 | P2RX7 (0.38) | HCRTR1HCRTR2SYKGAA | |
| SCHEMBL19699482 | 0.70 | ALDH1A1 (0.51) | LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL10311686 | 0.70 | ALDH1A1 (0.51) | LMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | KCNB1 2292/4885ACACB 3910/4885SMN1; SMN2 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.